Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894282 | 1.00 | GPR119 (0.34) | GPR119GPR183PARP1RIPK1GABRA5 | |
| SCHEMBL2895884 | 0.94 | GPR119 (0.35) | GPR119GPR183PARP1RIPK1GABRA5 | |
| SCHEMBL2895880 | 0.94 | GPR119 (0.35) | GPR119GPR183PARP1RIPK1GABRA5 | |
| SCHEMBL2888195 | 0.91 | GPR119 (0.35) | GPR119GPR183PARP1MAPTNPC1 | |
| SCHEMBL2891418 | 0.91 | GPR119 (0.38) | GPR119GPR183PARP1MAPTNPC1 | |
| SCHEMBL2893913 | 0.89 | GPR119 (0.35) | GPR119GPR183PARP1MAPT | |
| SCHEMBL2906289 | 0.89 | HDAC4 (0.37) | GPR119GPR183 | |
| SCHEMBL3663119 | 0.89 | GPR119 (0.37) | GPR119GPR183PARP1MAPTNPC1 | |
| SCHEMBL2894063 | 0.87 | GPR119 (0.37) | GPR119GPR183PARP1MAPTNPC1 | |
| SCHEMBL2895563 | 0.87 | GPR119 (0.38) | GPR119GPR183S1PR1S1PR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | GPR119, GIPR, GPR39 | GPR119 1/4885GPR183 30/4885PARP1 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.